Skip to main content

Table 1 Baseline characteristics of the patients

From: Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma

  N = 58
Age (years) 60 (33–86)
Sex, male 53 (91.4)
Etiology of HCC
 HBV  
 Others  
Child-Pugh score
 A5 38 (65.5)
 A6 20 (34.5)
ALBI grade
 1 26 (44.8)
 2 32 (55.2)
AFP 594 (10–9242)
PIVKA-II 4899 (796–25,522)
BCLC stage
 B 15 (25.9)
 C 43 (74.1)
Vascular invasion (yes) 18 (31.0)
Extrahepatic meta (yes) 36 (62.1)
 Lung 20 (34.5)
 Lymph node 10 (17.2)
 Bone 8 (13.8)
 Adrenal gland 2 (3.4)
 Others 9 (15.5)
Sorafenib treatment duration (months) 2.9 (1.5–28.1)
  1. Values are presented as median (interquartile range) or number (%) of patients
  2. ALBI albumin–bilirubin, HCC hepatocellular carcinoma, HBV hepatitis B virus, BCLC Barcelona Clinic Liver Cancer, AFP alpha-fetoprotein, PIVKA protein induced by vitamin K absence or antagonist